The Biomedical Catalyst (BMC) is a unique partnership between the MRC and Innovate UK, providing responsive and effective support to the most innovative life sciences opportunities regardless of scientific approach. The BMC aims to de-risk innovative science and commercialise ideas arising out of academia and industry helping UK SMEs to develop into competitive and sustainable organisations. This accelerates the progress of novel products to market, facilitates onward investment and bridges “the valley of death”.
MRC supports academically-led feasibility research through the Confidence in Concept which is open to institutions but not individual researchers. Academic-led applications for Early and Late Stage awards are primarily administered through the Developmental Pathway Funding Scheme (DPFS).
Since BMC launched in April 2012, the scheme has awarded more than £250m funding, matched by ~£150m of private finance, to over 300 projects seeking to develop a wide range of therapies, diagnostics and devices. Project case studies and a complete list of projects (PDF, 463KB) funded under the Biomedical Catalyst scheme are available online.